Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. - Wikidata - awgldk - TriplyDB

Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.

Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.

http://www.wikidata.org/entity/Q51986028

about

SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people Plasma and Cerebrospinal fluid (CSF) Abeta42 for the differential diagnosis of Alzheimer's disease dementia in participants diagnosed with any dementia subtype in a specialist care setting Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer's disease Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Biological markers of amyloid beta-related mechanisms in Alzheimer's disease Spatial correlation between brain aerobic glycolysis and amyloid-β (Aβ ) deposition 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment Protein aggregation in the brain: the molecular basis for Alzheimer's and Parkinson's diseases Biomarkers of Alzheimer's disease Active and passive immunotherapy for neurodegenerative disorders Candidate mechanisms underlying the association between sleep-wake disruptions and Alzheimer's disease The past and the future of Alzheimer's disease CSF biomarkers-a journey toward validated biochemical tests covering the whole spectrum of molecular events Fluid Biomarkers in Clinical Trials of Alzheimer's Disease Therapeutics Autosomal Dominant Alzheimer Disease: A Unique Resource to Study CSF Biomarker Changes in Preclinical AD Role of HIV in amyloid metabolism Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers The relevance of beta-amyloid on markers of Alzheimer's disease in clinically normal individuals and factors that influence these associations New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs Preclinical Alzheimer disease: identification of cases at risk among cognitively intact older individuals Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-β(1-42) and τ proteins as Alzheimer disease biomarkers Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease Mild cognitive impairment. Part 2: Biological markers for diagnosis and prediction of dementia in Alzheimer's disease Genetic markers in biological fluids for aging-related major neurocognitive disorder qPR: An adaptive partial-report procedure based on Bayesian inference.The use of cerebrospinal fluid and neuropathologic studies in neuropsychiatry practice and research Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography Role of family history for Alzheimer biomarker abnormalities in the adult children study Evidence of association between sleep quality and APOE ε4 in healthy older adults: A pilot study Atrophy rates in asymptomatic amyloidosis: implications for Alzheimer prevention trials Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia CSF T-Tau/Aβ42 predicts white matter microstructure in healthy adults at risk for Alzheimer's disease Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease.The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers PET amyloid-beta imaging in preclinical Alzheimer's disease

P2860

Q21144971-A8E30F1A-2A46-423A-96A6-31B3ED3D2336 Q22253051-EC770F94-A8A5-4E88-9918-ECC19D150203 Q24201276-67BD8D35-259E-44AB-8488-F83D5C4E0B1E Q24312938-6D863C81-B2C6-4828-B675-3B9A0C346D2B Q24594531-7742F96D-44A7-49DB-A67E-24DBA982B1DF Q24595802-A3DD52AF-CFD0-418E-BA14-C0A0A545A614 Q24622136-70A876E6-DC92-4A93-849D-9A6717A7FA3C Q24631814-DFD5809F-C69C-4B0F-99D4-973EC1CA9340 Q24648319-622532C5-4D32-49D3-B5CC-2B5FC34DDC68 Q24650014-C8C8DA10-26D0-4CEC-A1EB-A9DEB3739C27 Q24650667-D637917C-D81C-49E9-80E4-244383FB5FFA Q24657879-6EB38CC5-43C7-4E3E-B727-88EE9E09D16D Q26753192-8142BCB7-0E2E-4C00-AE81-DB4AF4517B78 Q26781635-56A8E27F-374B-488D-B607-54ACFC2C803E Q26784569-124CF09C-E684-4EDD-A5F0-4084BF784785 Q26801666-1D4B1916-39CB-42B1-AC5B-BDA39C27D05F Q26824179-B5E5C50C-90A1-494A-8895-D08ED9E59AFE Q26825442-F3FC5F38-4CFA-441C-86B0-160746B21573 Q26830467-A29FC362-7A2E-4117-8ED0-A15884C60AAA Q26866006-2636A92C-0736-44D9-8758-20101695922E Q26995405-818F688E-3A7E-4C91-BA91-3FF7E025D032 Q27008249-F1720E52-F52A-4399-8994-2E520EFAB826 Q27009411-3A16FC9F-87BF-4255-9C79-920AD45E801F Q27027319-CE690738-0648-43CD-AB84-FC2447554757 Q27027348-6770277A-7E38-4D41-8924-BC04E8748996 Q27335564-2E8C59AF-C101-498C-AB71-CD0FC4AFDFBB Q28088291-81D85FCE-0D09-4051-B45B-90EC2CB80212 Q28273817-6D5D226D-E23B-453F-BA85-D82B7968234B Q28383467-5AE26241-FE91-4CF1-83AE-034CEAE68262 Q28392997-6B4B8468-6372-4F27-A801-FE812A7AEC09 Q28488143-D6E2F531-C6E2-4860-A2C7-B0134C5EEB63 Q28705235-31E7F8B9-D49B-41CC-B5FD-D5B288920BAD Q28728773-ADBD5969-42CF-4AB0-AAB0-7B9B419016B0 Q28740917-7C9F8FC9-8971-478B-B4F8-25196416F100 Q28743561-849C6048-7471-40EE-A38C-2155F34B21AB Q29417137-E0D1A963-87E0-4C24-B9A2-43965259BABB Q29614406-F3182587-9082-45D4-A763-A2DA8BB524A2 Q29614407-4A3DA522-5AF4-42E0-949D-70D85880B9B6 Q29620245-4A3AEFC5-87C6-408E-AFFF-43CDF3DBB18C Q30040695-4DCF1AE8-99B4-46CF-A00B-C500A8CD3264

P2860

Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.

http://www.wikidata.org/entity/Q51986028

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年学术文章

@wuu

2006年学术文章

@zh

2006年学术文章

@zh-cn

2006年学术文章

@zh-hans

2006年学术文章

@zh-my

2006年学术文章

@zh-sg

2006年學術文章

@yue

2006年學術文章

@zh-hant

name

Inverse relation between in vi ...... pinal fluid Abeta42 in humans.

@en

Inverse relation between in vi ...... pinal fluid Abeta42 in humans.

@nl

type

label

Inverse relation between in vi ...... pinal fluid Abeta42 in humans.

@en

Inverse relation between in vi ...... pinal fluid Abeta42 in humans.

@nl

prefLabel

Inverse relation between in vi ...... pinal fluid Abeta42 in humans.

@en

Inverse relation between in vi ...... pinal fluid Abeta42 in humans.

@nl

P1433

Q51986028-9D362191-7CA2-4932-804C-48B960F5C703

P1476

Q51986028-7E74E16C-09F5-48EF-AF88-2BBB46075204

P2093

Q51986028-300C6D62-3BE9-4415-A9D8-7A26617355DB

Q51986028-4ABA2A7D-28CD-4CC6-8AF9-E21B406A6C1B

Q51986028-6DDD657D-BA42-426A-82E2-A01E97127401

Q51986028-7082830A-C9ED-428C-A896-BC53AA2123F3

Q51986028-790B83B5-2DDF-4D56-9073-3F909FC0F6E7

Q51986028-920B7FDA-81EB-4D8D-AB98-5952C888E852

Q51986028-9BCD5B71-B65E-4BCD-B35A-5F63741667DD

Q51986028-B02FFA0F-2481-41E9-8F5B-76C9F62B3F5E

Q51986028-C6AA85A6-9DE6-4022-B33A-75B0F3998D97

Q51986028-D1D39A48-1699-4BED-A96A-ABD6FB78CAD9

P304

Q51986028-9A1A9283-BE91-4582-B30A-B0AE02B21829

P31

Q51986028-978F0FF4-3B72-4DBE-B8D1-E7341F4B3FD1

P356

Q51986028-17939D34-C7BE-474E-BC78-C0F1236792F4

P433

Q51986028-8F36114F-0F35-47A1-9B20-5F9EFB9F1692

P478

Q51986028-E62979B4-B2CC-47CF-806A-C3E112C9D1A8

P50

Q51986028-6A49B0DE-0AB7-481F-94EF-3963F1F76159

Q51986028-776CE404-D79C-4AD5-9F57-BAEA2A37CCC5

Q51986028-FD4DDB2B-BB48-4786-AE1A-4AC1AA44F233

P577

Q51986028-5B4C53FC-2F9D-49AA-9E3C-BAFD00EA9E81

P5875

Q51986028-59DBD630-2A91-47B5-AB95-F78A04A1638F

P698

Q51986028-A07598C2-D638-431F-9487-D17C88AE098C

P921

Q51986028-604ADDD5-0E66-41CA-8E84-318BCC06E253

P356

P1433

Annals of Neurology

P1476

Inverse relation between in vi ...... pinal fluid Abeta42 in humans.

@en

P2093

Aarti R Shah

http://www.w3.org/2001/XMLSchema#string

Carmen S Dence

http://www.w3.org/2001/XMLSchema#string

Chester A Mathis

http://www.w3.org/2001/XMLSchema#string

Gina N LaRossa

http://www.w3.org/2001/XMLSchema#string

John C Morris

http://www.w3.org/2001/XMLSchema#string

Mark A Mintun

http://www.w3.org/2001/XMLSchema#string

Michael L Spinner

http://www.w3.org/2001/XMLSchema#string

Robert H Mach

http://www.w3.org/2001/XMLSchema#string

Sang-Yoon Lee

http://www.w3.org/2001/XMLSchema#string

Steven T DeKosky

http://www.w3.org/2001/XMLSchema#string

P304

512-519

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ANA.20730

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

59

http://www.w3.org/2001/XMLSchema#string

P50

William E. Klunk

David M. Holtzman

P577

2006-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7399410

http://www.w3.org/2001/XMLSchema#string

P698

16372280

http://www.w3.org/2001/XMLSchema#string

P921

cerebrospinal fluid